Clinical trials: Advanced Digestive System Tumor
Squamous Cell Carcinoma of the Head and Neck (SCCHN), Ovarian Carcinoma-Enrollment Completed
A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
This is a study to determine the clinical benefit (how well the drug works), safety, and tolerability of combining varlilumab and nivolumab (also known as Opdivo® , BMS-936558).
- Conditions
- Squamous Cell Carcinoma of the Head and Neck (SCCHN), Ovarian Carcinoma-Enrollment Completed, Colorectal Cancer (CRC)-Enrollment Completed, Renal Cell Carcinoma (RCC) (Phase ll Only)
- Trial name
- NCT02335918
- Testing
- Combination of varlilumab and nivolumab
- Where
- 19 sites in United States
- Volunteers
- 175 people
- Sponsor
- Celldex Therapeutics
Gastric Cancer
Chemotherapy Options for the First Line Chemotherapy in Elderly Patient With Advanced Gastric Cancer
The investigators compare the overall survival between combination chemotherapy and monochemotherapy as a first-line chemotherapy in elderly patients with metastatic or recurrent gastric cancer.
- Trial name
- NCT02114359
- Testing
- Capecitabine/cisplatin, S-1/cisplatin, Capecitabine/oxaliplatin
- Where
- 14 sites in South Korea
- Volunteers
- 111 people
- Sponsor
- Seoul National University Hospital
Multiple Myeloma, Lymphoma, Large B-Cell, Diffuse
Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma
The main purpose of this first in human study with CC-122 is to assess the safety and action of a new class of experimental drug (Pleiotropic Pathway Modulator) in patients with advanced tumors unresponsive to standard therapies…
- Conditions
- Multiple Myeloma, Lymphoma, Large B-Cell, Diffuse, Pleiotropic Pathway Modifier, Glioblastoma
- Trial name
- NCT01421524
- Testing
- CC-122
- Where
- 39 sites in United States, Belgium and 3 more
- Volunteers
- 271 people
- Sponsor
- Celgene
HCC - Hepatocellular Carcinoma, NSCLC (Advanced Non-small Cell Lung Cancer)
Universal CAR-T Cells (REVO-UWD-03) for Advanced Hepatocellular Carcinoma and Lung Cancer
This is an investigator initiated trial to assess the efficacy and safety of a GPC3-targeting CAR-T therapy (REVO-UWD-03) in the HCC and Lung Cancer.
- Trial name
- Wondercel-UWD3 (NCT06653023)
- Testing
- Universal CAR-T cells injection for treating HCC and NSCLC, MMF Immunosuppression
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Wondercel Biotech (ShenZhen)
Hepatocellular Carcinoma
DKN-01 Inhibition in Advanced Liver Cancer
This clinical trial is a prospective, open label, single arm oncological phase I/II trial in patients with hepatocellular carcinoma and WNT signaling alterations.
- Trial name
- NCT03645980
- Testing
- DKN-01 300 mg, DKN-01 600 mg, Sorafenib
- Where
- 6 sites in Germany
- Volunteers
- 70 people
- Sponsor
- Johannes Gutenberg University Mainz
Adenocarcinoma, Adenocystic Carcinoma
The Registry of Oncology Outcomes Associated With Testing and Treatment
This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation.
- Conditions
- Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer
- Trial name
- ROOT (NCT04028479)
- Testing
- Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P)
- Where
- 2 sites in United States
- Volunteers
- 167 people
- Sponsor
- Taproot Health
Liver Cancer
Chidamide Combined With Sintilimab and Bevacizumab for the First-line Treatment of Advanced Liver Cancer
The purpose of this study is to explore the safety and tolerability of chidamide in combination with Sintilimab and bevacizumab in patients with advanced liver cancer, to determine the recommended dose for this combination…
- Trial name
- NCT06408623
- Testing
- chidamide combined with Sintilimab and bevacizumab
- Volunteers
- 48 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Rectal Cancer
Neoadjuvant FOLFOXIRI Versus CapeOX Chemotherapy for Local Advanced Rectal Cancer
This is a phase III randomized controlled trial comparing the efficacy and safety of FOLFOXIRI versus CapeOX as neoadjuvant regimen in treating patients with middle and upper locally advanced (MRI T3-4 or N+) rectal cancer.
- Trial name
- RCNAC (NCT05201430)
- Testing
- FOLFOXIRI, CapeOX
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Fudan University
Esophageal Squamous Cell Carcinoma
Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 )
This is a randomized, double-blind multi-center, phase III study comparing the efficacy and safety of sintilimab or placebo in combination with chemotherapy as first-line treatment in subjects with unresectable, locally advanced…
- Trial name
- NCT03748134
- Testing
- Sintilimab, Cisplatin, Paclitaxel
- Where
- 48 sites in United States, Australia and 5 more
- Volunteers
- 746 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Esophageal Cancer
A Phase II Exploratory Clinical Trial of Multiple Drug Combinations in the Treatment of Advanced Esophageal Squamous Cell Carcinoma
The purpose of this study is to observe and evaluate the efficacy and safety of multiple drug combinations in the treatment of advanced esophageal squamous cell carcinoma.
- Trial name
- NCT03736863
- Testing
- Apatinib+ SHR-1210（Camrelizumab）, Apatinib+ SHR-1316（Adebrelimab）, SHR-1316（Adebrelimab）+SHR-A2009
- Where
- China
- Volunteers
- 147 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Esophageal Squamous Cell Carcinoma
A Phase II Study of SHR-1210 vs Placebo as Consolidation Chemotherapy After Radical Concurrent Chemoradiotherapy in Locally Advanced ESCC
The purpose of this study is to observe and evaluate the efficacy and safety of SHR-1210 vs placebo as consolidation chemotherapy after radical concurrent chemoradiotherapy for unresectable locally advanced ESCC.
- Trial name
- NCT03817658
- Testing
- SHR-1210
- Where
- China
- Volunteers
- 725 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Gastrointestinal Stromal Tumors
A Study of BBI503 in Adult Patients With Advanced Gastrointestinal Stromal Tumors
This is an open label, multi-center, phase II study of BBI503 administered to adult patients with advanced gastrointestinal stromal tumor who have exhausted all currently approved standard anti-cancer treatment options.
- Trial name
- NCT02232620
- Testing
- BBI503
- Where
- Canada
- Volunteers
- 2 people
- Sponsor
- Sumitomo Pharma America, Inc.
Gastric Cancer
Phase II Study of DC Versus 5-FU/CF as Chemotherapy and Concurrent Chemoradiotherapy for Locally Advanced Gastric Cancer
Concurrent chemoradiotherapy has been demonstrated a significant improvement in overall survival and disease-free survival according to Intergroup Trial 0116 in patients with gastric cancer after surgical resection.
- Trial name
- NCT01889303
- Testing
- DC, concurrent chemoradiotherapy with 5-FU/CF, radiation
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Wuhan University
Colorectal Cancer
A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer
This study is an open, multi-center, phase II study, aiming to evaluate the safety, tolerability and efficacy of AMT-676 combined with 5-fluorouracil, leucovorin, bevacizumab (or cetuximab) in participants with advanced…
- Trial name
- NCT07474727
- Testing
- AMT-676, 5-FU, Leucovorin
- Where
- 19 sites in China
- Volunteers
- 180 people
- Sponsor
- Multitude Therapeutics Inc.
Colorectal Cancer
Monoclonal Antibody F19 in Treating Patients With Advanced or Metastatic Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00004042
- Testing
- monoclonal antibody F19, iodine I 131 monoclonal antibody F19
- Where
- 3 sites in United States, Australia
- Volunteers
- 24 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non-Small Cell Lung Cancer, Colorectal Cancer
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
This is a Phase 1 study of FT836 administered in participants with advanced solid tumors. The primary objectives of the study are to evaluate the safety and tolerability of FT836 with or without chemotherapy and/or trastuzumab or…
- Conditions
- Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer
- Trial name
- NCT07216105
- Testing
- FT836, Cetuximab, Trastuzumab
- Where
- 5 sites in United States
- Volunteers
- 119 people
- Sponsor
- Fate Therapeutics
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction
Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer
This pilot phase II trial studies how well giving bevacizumab and combination chemotherapy together before surgery works in treating patients with locally advanced esophageal or stomach cancer.
- Conditions
- Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach
- Trial name
- NCT01212822
- Testing
- bevacizumab, oxaliplatin, leucovorin calcium
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Fox Chase Cancer Center
Breast Cancer, Gastric Cancer
Biological Therapy in Treating Patients With Advanced Cancer
RATIONALE: A person's white blood cells mixed with tumor proteins may make the body build an immune response to kill tumor cells.
- Conditions
- Breast Cancer, Gastric Cancer, Ovarian Cancer
- Trial name
- NCT00005956
- Testing
- HER-2/neu intracellular domain protein, therapeutic autologous dendritic cells
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Duke University
Gastric Cancer
Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-gastric Cancer
The primary objective of this study is to demonstrate that addition of cetuximab to 1st-line treatment with capecitabine (Xeloda, X) and cisplatin (P) [XP] chemotherapy regimen has a clinically relevant benefit for subjects with…
- Trial name
- EXPAND (NCT00678535)
- Testing
- Cetuximab, Capecitabine, Cisplatin
- Where
- 130 sites in Argentina, Australia and 23 more
- Volunteers
- 904 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Esophageal Cancer, Lung Cancer
Decitabine in Treating Patients With Unresectable Lung or Esophageal Cancer or Malignant Mesothelioma of the Pleura
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of decitabine in treating patients who have unresectable…
- Conditions
- Esophageal Cancer, Lung Cancer, Malignant Mesothelioma, Metastatic Cancer
- Trial name
- NCT00019825
- Testing
- decitabine
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.